Replies to post #10913 on Ayala Pharmaceuticals Inc (ADXS)

[ignatiusrielly35]

Personally, I'm still trying to figure out what, supposedly, Dan did wrong to justify the current pps. Progress every indication in an efficient and successful manner, while obtaining Fast Track, SPA, etc.? Sign a huge $500 million deal with Amgen for a pre-clinical platform? Raise money once in a while, which every clinical biotech needs? Oh, wait, I forgot, he and management issued themselves a couple of hundred thousand options. Quite unprecedented. A "first" in corporate America. lol